Hikma Pharmaceutical reported $590M in Cost of Sales for its first fiscal semester of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cost Of Sales Change
Artemis Alpha ATS:LN GBP 507K 125K
AstraZeneca AZN:LN USD 2.12B 214M
Bayer BAYN:GR EUR 4.25B 1.43B
Fresenius FRE:GR EUR 7.75B 414M
Fresenius Medical Care FMS:US EUR 3.74B 326.95M
Galapagos GLPG:NA EUR 2.39M 240K
GlaxoSmithKline GSK:LN GBP 2.39B 250M
Hikma Pharmaceutical HIK:LN USD 590M 62M
Lonza Group LONN:SW CHF 1.79B 14M
Merck MRK:GR EUR 2.15B 38M
Orion ORNBV:FH EUR 136.1M 25.9M
Recordati REC:IM EUR 154.92M 2.52M